Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Abstracts

Clinical pathology selected abstracts

September 2025—Severe acute respiratory syndrome coronavirus 2 infection can lead to post-acute sequelae, or a condition known as long COVID. The World Health Organization defines long COVID as any symptoms that typically present within three months of acquiring COVID-19 and that persist for at least two months. Long COVID generally manifests as fatigue, pulmonary symptoms, and cognitive dysfunction. The biological mechanisms of long COVID are not well understood. Changes in the serotonin system may lead to cognitive changes, while mitochondrial changes may lead to fatigue, and complement and platelet activation to vascular disease.

Anatomic pathology selected abstracts

September 2025—The efficacy of human epidermal growth factor receptor 2 antibody-drug conjugate therapy for treating HER2-low breast cancers necessitates more accurate and reproducible HER2 IHC scoring. The authors conducted a study to validate the performance and utility of a fully automated artificial intelligence (AI) solution for interpreting HER2 IHC in breast carcinoma. In the two-arm multireader study of 120 HER2 IHC whole slide images from four sites, four surgical pathologists assessed HER2 scoring with and without the aid of an AI solution. Both arms of the study were compared with high-confidence ground truth established by agreement of at least four of five breast pathology subspecialists according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 and 2023 guidelines. The mean interobserver agreement among the ground truth pathologists across all HER2 scores was 72.4 percent (n =120).

Molecular pathology selected abstracts

September 2025—When someone dies suddenly and unexpectedly, a forensic autopsy is often performed to identify the manner and cause of death. However, up to 30 percent of autopsies fail to identify any underlying anatomic or toxicologic etiologies, and the autopsy classification may be sudden unexplained death. This is particularly concerning in young people, in whom the cause could be an inherited genetic condition that could also affect family members. Therefore, postmortem genetic testing, also known as a molecular autopsy, may have utility in identifying underlying inherited diseases that could contribute to death. In many cases, sudden death is due to cardiac factors, but the type of cardiac dysfunction may depend on age.

Clinical pathology selected abstracts

August 2025—The Accreditation Council for Graduate Medical Education (ACGME) oversees graduate medical education and closely monitors resident wellness. In 2017, the ACGME published findings from a national study outlining the causes of death among residents and fellows from 2000 through 2014. The most common overall cause of death was malignant neoplasm, and it was the leading cause of death among female residents and fellows. Suicide was the leading cause of death for male residents and the second leading cause for females. Twenty-three percent of deaths by suicide occurred in the first academic quarter of trainees’ first year in their medical programs.

Anatomic pathology selected abstracts

August 2025—Certain subtypes of colorectal carcinoma pose diagnostic challenges in daily practice due to sometimes overlapping morphologic and immunohistochemical features and are associated with worse prognoses than poorly differentiated adenocarcinoma not otherwise specified (PDA-NOS). Other variants of poorly differentiated colon cancers with solid growth patterns that have, anecdotally, been recognized as posing diagnostic challenges include large cell neuroendocrine carcinoma (LCNEC), medullary carcinoma (MC), undifferentiated carcinoma (UC), and lymphoepithelioma-like carcinoma (LELC). The authors conducted a study to determine survival outcomes between patients with poorly differentiated adenocarcinoma and those with a variant carcinoma morphology that may affect prognosis. They also analyzed interobserver agreement among gastrointestinal pathologists at their institution in subclassifying poorly differentiated colorectal carcinoma. All consecutive patients with diagnoses of PDA-NOS, MC, LCNEC, UC, and LELC between July 2018 and July 2023 were included.

Molecular pathology selected abstracts

August 2025—Childhood malignancies such as Wilms tumor—the most common type of kidney cancer in children—exhibit very few DNA changes when tested by traditional sequencing methods. Some of these types of tumors have fewer genetic anomalies than age-matched normal tissue. This raises the question, How can such genetically “quiet” malignancies emerge and progress without conventional driver mutations? To address this question, the authors employed high-resolution, ultra-deep sequencing to determine if hypomutation in juvenile kidney cancers characterized by a paucity of mutations, specifically Wilms tumor, is genuine or an artifact of conventional analytical constraints. By applying high-resolution duplex sequencing (Nanoseq) to Wilms tumors and matched normal kidneys from six pediatric patients, including four infants and two school-age children, the authors showed that standard bulk whole genome sequencing significantly underestimates the mutational burden in tumors from infants.

Clinical pathology selected abstracts

July 2025—A large number of cancers remain undetected until later stages, including lung, colorectal, cervical, ovarian, pancreatic, and prostate cancers. The U.S. Preventive Services Task Force recommends screening based on age and other risk factors. It is estimated that more than 4 million cancers have been avoided due to early screening methods. Efforts are being made to develop cancer-screening tests that are easier to perform and less invasive and that detect multiple types of cancer, with the intent of reducing cancer-related morbidity and mortality. Multicancer early detection (MCED) assays depend on circulating cell-free DNA to detect a shared single cancer signal.

Anatomic pathology selected abstracts

July 2025—Intraductal oncocytic papillary neoplasm of the pancreas is a recently recognized pancreatic tumor. The authors conducted a study to generate a comprehensive and quantitative summary of various aspects of intraductal oncocytic papillary neoplasms (IOPN). They searched the PubMed, Scopus, and Embase databases for studies reporting on pancreatic IOPN. Clinicopathologic, immunohistochemical, and molecular data were extracted from the studies and summarized. A comparative analysis of the molecular alterations of IOPN in juxtaposition with the typical molecular profile of conventional pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts was subsequently conducted.

Molecular pathology selected abstracts

July 2025—Liver damage can result in a build up of scar tissue, or fibrosis, a hallmark of chronic liver disease (CLD). The latter has been attributed to a variety of risk factors, including viruses (primarily hepatitis B and C), obesity, and alcohol abuse. Furthermore, some patients have a genetic predisposition for the disease. Alpha-1 antitrypsin (A1AT) deficiency and hereditary hemochromatosis are two such inherited disorders that cause hepatocyte stress and damage. In A1AT deficiency, mutations in the SERPINA1 gene produce abnormal variants of the A1AT protein, which can accumulate in the liver and lead to hepatocyte damage. Mutations in the HFE gene are responsible for hereditary hemochromatosis.

Pathology informatics selected abstracts

July 2025—Computational pathology has largely focused on analyzing tissue slides and overlooked worthwhile information in gross images. Recognizing this, the authors introduced a novel deep learning model based on Swin Transformer architecture and called Swin Transformer-based Gross Features Detective Network (SGFD-network). They sought to summarize and classify the gross examination characteristics of ovarian epithelial tumors by analyzing images of gross specimens using this deep learning approach. The SGFD-network is especially useful for distinguishing borderline tumors with microinvasive components from frank carcinomas. This capability is crucial during frozen section analysis, in which limited sampling and time pressures often challenge diagnostic accuracy.

MARKETPLACE

TRENDING